Supported by real clinical evidence — where results are demonstrated through data-D&D Healthcare

Persistent troubles caused by gastric Helicobacter pylori, recurring stomach discomfort, and difficulties eradicating drug-resistant strains are long-standing gastrointestinal issues plaguing countless people. A vast array of gastrointestinal care products are available on the market, yet most lack authoritative clinical data for validation. In contrast, the gastric probiotics formulated with D&D patented strains have all conclusions backed by authentic, authoritative clinical trials, demonstrating their robust stomach-protecting efficacy through multi-dimensional measured data.

I. Potent Co-Aggregation Capacity: Firmly Bind to Helicobacter pylori

The core capability of probiotics to block Helicobacter pylori colonization lies in co-aggregation: the strains bind to Helicobacter pylori, reducing its chances of adhering to the gastric mucosa.

Flow cytometry test results reveal that the D&D patented strains achieve a **62.2% co-aggregation rate against Helicobacter pylori**, considerably exceeding the 49.5% recorded by comparable German competitors. Supporting scanning electron microscope images further verify that, in comparison with reference strains, these patented strains generate far more co-aggregation complexes, delivering superior efficacy against Helicobacter pylori and curbing the adhesion of harmful bacteria to the stomach lining at the source.

II. Groundbreaking Clinical Outcome: 80% Eradication Rate for Drug-Resistant Helicobacter pylori

Antibiotic therapies often yield poor results against drug-resistant Helicobacter pylori, which explains why many individuals suffer repeated failed eradication attempts.

Based on authoritative double-blind clinical trials carried out by Nanfang Hospital, Southern Medical University (Clinical Trial Registration Numbers: NCT05483660, NCT06760897), eradication efficacy was assessed using the gold standard: ¹³C/¹⁴C urea breath tests. After 50 participants received intervention with the patented strains, the eradication rate for drug-resistant Helicobacter pylori reached 80.0%. Participants’ DOB values from breath tests dropped markedly post-intervention. This fully proves the strains can effectively regulate gastric microecology and specifically tackle drug-resistant Helicobacter pylori that antibiotics struggle to eliminate.

III. High Rate of Symptom Improvement: Comprehensive Relief from Gastric Discomfort

Beyond bacterial eradication, alleviating overall discomfort including acid regurgitation, belching and dull stomach pain is the most tangible health benefit for users.

The overall relief rate for combined gastrointestinal symptoms stood at **84.4%**, with most participants experiencing significant alleviation of bloating, acid reflux, postprandial stomach upset and other digestive issues;
The improvement rate of gastric health indicators reached **81.25%**, bringing positive adjustments to the intragastric flora balance and overall gastric condition.
Bar charts and scatter plot statistics from controlled experiments clearly illustrate the disparities between the intervention group and the regular control group, intuitively showcasing the patented strains’ holistic benefits for gastric health.

Source: Double-blind clinical study reports conducted by Nanfang Hospital, Southern Medical University (Clinical Trial Registration Nos. NCT05483660 and NCT06760897), together with flow cytometry analytical data. *Results derived from exploratory clinical research and should not be interpreted as therapeutic claims.

Supported by real clinical evidence — where results are demonstrated through data

I. Potent Co-Aggregation Capacity: Firmly Bind to Helicobacter pylori

II. Groundbreaking Clinical Outcome: 80% Eradication Rate for Drug-Resistant Helicobacter pylori

III. High Rate of Symptom Improvement: Comprehensive Relief from Gastric Discomfort

分享至微信分享

分享至微信

分享至微信